A KAUST-led team developed NIRVANA, a portable, briefcase-sized device for rapid detection and sequencing of SARS-CoV-2, influenza, and other viruses. The test utilizes isothermal recombinase amplification (RPA) and was validated on clinical samples and wastewater. NIRVANA can differentiate SARS-CoV-2 strains and doesn't require expensive infrastructure. Why it matters: This innovation enables rapid, decentralized virus detection and surveillance, crucial for pandemic response and monitoring new variants across the region.
KAUST researchers developed a new model integrating SIR compartment modeling in time and a point process modeling approach in space-time, also considering age-specific contact patterns. They used a two-step framework to model infectious locations over time for different age groups. The model demonstrated improved predictive accuracy in simulations and a COVID-19 case study in Cali, Colombia, compared to existing models. Why it matters: This model can assist decision-makers in identifying high-risk locations and vulnerable populations for better disease control strategies in the region and globally.
SaudiVax, located in the KAUST Research & Technology Park, is collaborating with the University of Pittsburgh and Merck France to develop a COVID-19 antibody injection. The antibody both protects against potential infection and neutralizes the virus in those already infected. SaudiVax is utilizing KAUST expertise and has contracted with Merck France for manufacturing since suitable facilities are not yet available in Saudi Arabia. Why it matters: This partnership highlights the growing biopharmaceutical capabilities in Saudi Arabia and the potential for KAUST to serve as a hub for medical innovation in the region.
KAUST Professor Xin Gao formed part of the Rapid Research Response Team (R3T) to address the COVID-19 pandemic. Gao's team developed and deployed an AI system to assist clinicians in improving the accuracy of COVID-19 diagnoses. The lecture outlines how the AI system was built and implemented. Why it matters: This showcases how GCC academic institutions are leveraging AI to address pressing healthcare challenges.
KAUST Professor Hernando Ombao is leading the Biostatistics Group to develop statistical models for projecting hospitalization surges during the COVID-19 pandemic. The group uses techniques like time series analysis and stationary subspace analysis to understand complex biological processes. The models aim to provide public health officials with accurate hospitalization estimates under varying scenarios. Why it matters: This research contributes to preparedness and resource allocation in healthcare systems during public health crises, with potential applications beyond COVID-19.
KAUST researchers are developing iSCAN, a rapid, field-deployable COVID-19 test using RT-LAMP coupled with CRISPR-Cas12. The iSCAN system is designed for rapid, specific detection of SARS-CoV-2 and can be deployed by untrained personnel. The researchers are benchmarking iSCAN against commercial kits and seeking emergency use authorization from the Saudi FDA. Why it matters: A rapid, accurate, and field-deployable COVID-19 test could significantly improve pandemic management and control in Saudi Arabia and beyond.
KAUST's Rapid Research Response Team (R3T), including Professor Samir Hamdan, is working to understand and counteract the spread of COVID-19. The team assembled a complete homemade, one-step RT-PCR test, comparable to commercial kits, with a patent-free manufacturing recipe. KAUST R3T is also researching faster, more accurate point-of-care tests, including a CRISPR-based molecular test. Why it matters: This research provides accessible testing solutions and contributes to more effective and rapid detection methods for combating viral spread in the region and globally.
KAUST is offering access to its Shaheen II supercomputer and other computing resources for COVID-19 research projects by researchers across the Kingdom. Researchers can apply for computing allocations by submitting a proposal to [email protected]. The resources available include Shaheen II, the Ibex cluster, and support from KSL staff scientists. Why it matters: This initiative will accelerate COVID-19 research in Saudi Arabia by providing access to advanced computing infrastructure and expertise.
The KAUST Pathogen Genomics Laboratory (PGL), led by Professor Arnab Pain, is using DNA and RNA sequencing to study the SARS-CoV-2 virus. The lab is part of KAUST's Rapid Research Response Team (R3T), supporting Saudi healthcare stakeholders in combating COVID-19. Pain and his Ph.D. student Sharif Hala are partnering with the Saudi-CDC and Ministry of Health hospitals to sequence Saudi SARS-CoV-2 samples. Why it matters: This effort provides crucial data for understanding and monitoring the virus's spread and evolution within the Kingdom, informing public health strategies.
A KAUST research team is using cellphone mobility data, Google searches, and social media to model and predict COVID-19 spread. The models aim to forecast cases in the coming weeks and inform resource allocation, including hospital beds and medical staff. The team is using aggregated and anonymized data from cellphone companies to respect people's privacy. Why it matters: Integrating real-time digital data with epidemiological modeling can improve the speed and effectiveness of public health responses in the region and globally.